Sarepta Therapeutics
SRPT
$17.97
+5.58%
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies and gene therapies for rare diseases, primarily neuromuscular disorders such as Duchenne muscular dystrophy (DMD). It is a distinct player in the rare disease space, with a portfolio of approved exon-skipping therapies and the landmark gene therapy ELEVIDYS, positioning it as a leader in the DMD treatment landscape. The current investor narrative is dominated by the commercial trajectory and regulatory path for ELEVIDYS, alongside intense scrutiny on the company's path to profitability, as recent quarterly results have shown significant revenue volatility and substantial net losses, sparking debate about its long-term cash burn and growth sustainability.…
SRPT
Sarepta Therapeutics
$17.97
Investment Opinion: Should I buy SRPT Today?
Rating: Hold. The core thesis is that while SRPT is deeply undervalued relative to its history and possesses a unique asset in ELEVIDYS, the severe and recent deterioration in fundamental metrics requires a 'show me' story before committing capital, making it suitable only for high-risk, speculative investors with a long time horizon.
Supporting evidence includes a trailing PS ratio of 1.03, which is at a significant discount to its own historical range and suggests substantial pessimism is priced in. Analyst consensus expects a revenue recovery to $1.31 billion, implying a forward PS of 1.72 and potential for multiple expansion. However, this optimism is countered by a catastrophic Q4 gross margin of 9.98%, a net margin of -32.45%, and a ROE of -62.55%, indicating the business is fundamentally broken in its current state. The stock's technical picture confirms the bearish sentiment, trading down 56.69% over the past year.
The two biggest risks that could invalidate a future Buy thesis are: 1) Gross margins failing to recover meaningfully above 30% in subsequent quarters, indicating the Q4 collapse was structural, and 2) Revenue continuing to decline or stagnate well below the $1.31 billion analyst estimate. This Hold rating would upgrade to a Buy if the PS ratio sustains below 1.0 alongside evidence of quarterly revenue stabilization and gross margin recovery above 50%. It would downgrade to a Sell on a sustained break below the $10.42 support level. Relative to its own history, the stock is undervalued, but relative to its current broken fundamentals, it is fairly valued, reflecting the high uncertainty.
Sign up to view all
SRPT 12-Month Price Forecast
SRPT presents a classic high-risk, high-reward biotech scenario. The valuation is compellingly cheap, but for a reason: recent operational performance has been disastrous. The investment thesis hinges entirely on whether the company can demonstrate that Q4 2025 was an anomaly. The base case of volatile, range-bound trading is most likely as the market demands proof of a turnaround. The stance would upgrade to bullish on concrete evidence of sustained gross margin recovery above 50% and quarterly revenue stabilization. It would turn bearish on a confirmed breakdown below the $10.42 support, signaling the market has lost faith in any near-term recovery.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Sarepta Therapeutics's 12-month outlook, with a consensus price target around $23.36 and implied upside of +30.0% versus the current price.
Average Target
$23.36
13 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
13
covering this stock
Price Range
$14 - $23
Analyst target range
Analyst coverage for SRPT consists of 13 firms, indicating a moderate level of institutional interest. The consensus sentiment is mixed, with recent actions including both 'Outperform'/'Overweight'/'Buy' ratings (from Oppenheimer, Mizuho, Wedbush, Guggenheim) and 'Underperform'/'Sell' ratings (from Needham, Citigroup, HC Wainwright & Co.), reflecting a high degree of uncertainty and bifurcated views on the company's prospects. The average revenue estimate for the next period is $1.31 billion, with a wide range from $1.05 billion to $1.56 billion, highlighting significant disagreement on the commercial outlook. The target price range is not explicitly provided in the data, but the wide dispersion in revenue estimates—a low of $1.05B to a high of $1.56B—implies a similarly wide potential valuation range. The high-end estimate likely assumes successful commercialization of ELEVIDYS, accelerated revenue growth, and improved margins, while the low-end likely prices in continued commercial challenges, competitive pressures, and persistent cash burn. The recent flurry of rating actions in Q1 2026, with no clear directional trend (maintains on both sides), suggests analysts are in a 'wait-and-see' mode, awaiting more consistent financial results or regulatory catalysts. The wide target spread is a classic signal of high uncertainty, common in biotech, where binary outcomes lead to divergent analyst models.
Bulls vs Bears: SRPT Investment Factors
The evidence currently favors the bear case, given the severe deterioration in fundamental metrics—specifically the 32.7% revenue decline and gross margin collapse to 9.98% in the most recent quarter. The stock's technical breakdown and deep underperformance reinforce this negative momentum. However, the bull case rests on the premise that these issues are transitory and that the stock's valuation at a PS ratio of 1.03, near historical lows, offers asymmetric upside if execution stabilizes. The single most important tension in the investment debate is the sustainability and trajectory of gross margins: whether the Q4 catastrophe was a one-time anomaly or a sign of permanent structural impairment in the company's profitability. The resolution of this issue will determine if Sarepta can return to a growth trajectory or faces continued financial distress.
Bullish
- Valuation at Historical Lows: The stock trades at a trailing PS ratio of 1.03, down from 5.09x in Q4 2025 and dramatically below historical peaks above 40x. This deep discount prices in extreme pessimism, offering significant upside potential if the company stabilizes its commercial execution.
- Analyst Revenue Recovery Expected: Analysts project a significant revenue rebound to an average of $1.31 billion for the next period, implying a forward PS of 1.72. The high-end estimate of $1.56 billion suggests a credible bull case where ELEVIDYS and exon-skipping therapies drive growth.
- Strong Liquidity Position: The company maintains a current ratio of 2.32, indicating sufficient short-term liquidity to fund operations despite cash burn. This provides a buffer to navigate near-term commercial challenges without immediate solvency risk.
- Potential for Margin Normalization: The catastrophic Q4 2025 gross margin of 9.98% is a severe outlier compared to the trailing twelve-month gross margin of 59.90%. A reversion towards historical margins on a recovering revenue base could dramatically improve profitability.
Bearish
- Severe Revenue Collapse & Volatility: Q4 2025 revenue of $442.93 million represents a 32.7% year-over-year decline, following extreme quarterly swings. This pattern indicates fundamental commercial instability, raising serious doubts about the sustainability of the business model.
- Deeply Unprofitable with High Cash Burn: The company reported a Q4 2025 net loss of $282.85 million and trailing twelve-month free cash flow of -$317.43 million. With a net margin of -32.45% and ROE of -62.55%, the path to profitability is unclear and dependent on external financing.
- Gross Margin Catastrophe in Q4: The gross margin collapsed to 9.98% in Q4 2025 from 75.04% in Q2 2025, suggesting massive one-time charges or severe pricing pressure. This extreme compression, if sustained, would make profitability impossible.
- Technical Downtrend & Underperformance: The stock is down 56.69% over the past year and trades just 15.3% above its 52-week low of $10.42. Its 1-month relative strength of -23.44 points confirms accelerating negative sentiment and failed breakout attempts.
SRPT Technical Analysis
The stock is in a pronounced and sustained long-term downtrend, with a 1-year price change of -56.69%, significantly underperforming the broader market, which gained 27.88% over the same period. Currently trading at $16.80, the price sits just 15.3% above its 52-week low of $10.42 and 61.7% below its 52-week high of $43.92, indicating it is deeply oversold and trading near the lower bounds of its annual range, which may suggest a potential value opportunity but also reflects severe bearish sentiment and fundamental challenges. The stock has a remarkably low beta of 0.255, suggesting it has been only about 25% as volatile as the market over the past year, though this low correlation is unusual for a biotech and may indicate idiosyncratic, company-specific risks driving its price action independent of broader market movements. Recent short-term momentum shows continued weakness, with the stock down 18.60% over the past month and 11.02% over the past three months, both periods starkly contrasting with the S&P 500's gains of 4.84% and 8.15%, respectively. This severe underperformance, evidenced by a 1-month relative strength of -23.44 points, confirms the downtrend's acceleration and highlights significant negative sentiment, likely driven by disappointing financial results or regulatory concerns. The price action shows a sharp spike to $23.77 on March 25, 2026, followed by an immediate rejection, indicating failed breakout attempts and reinforcing the dominant bearish pressure. Key technical levels are clearly defined, with major resistance at the 52-week high of $43.92 and immediate support at the 52-week low of $10.42. A sustained break below the $10.42 support would signal a new leg down and potentially trigger further panic selling. Conversely, a reversal would require a decisive move above the recent local high near $23-24. The stock's low beta of 0.255 is critical for risk assessment; it implies the stock's volatility is largely decoupled from the market, meaning traditional diversification benefits are limited, and investors are exposed primarily to binary company-specific events, which is typical for clinical-stage or commercially challenged biotechs.
Beta
0.20
0.20x market volatility
Max Drawdown
-72.3%
Largest decline past year
52-Week Range
$10-$25
Price range past year
Annual Return
+5.1%
Cumulative gain past year
| Period | SRPT Return | S&P 500 |
|---|---|---|
| 1m | +0.6% | -1.3% |
| 3m | -18.8% | +14.0% |
| 6m | -16.5% | +9.5% |
| 1y | +5.1% | +20.9% |
| ytd | -15.7% | +9.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SRPT Fundamental Analysis
Revenue trajectory is highly volatile and currently concerning, with the most recent Q4 2025 revenue of $442.93 million representing a significant 32.7% year-over-year decline. This follows a pattern of extreme quarterly swings: Q1 2025 revenue was $744.86 million, Q2 was $611.09 million, and Q3 was $399.36 million. The precipitous drop in Q4, alongside a gross margin collapsing to 9.98% from 75.04% in Q2, indicates severe commercial or operational disruption, likely related to inventory adjustments, rebates, or one-time charges for its DMD therapies. Segment data shows EXONDYS 51 contributed $115.6 million, VYONDYS 53 contributed $24.66 million, and AMONDYS 45 contributed $26.66 million in a recent period, but these figures alone cannot explain the drastic top-line contraction. Profitability remains a critical issue, with the company reporting a substantial net loss of $282.85 million in Q4 2025 and an EPS of -$2.74. The gross margin of 9.98% in that quarter is a catastrophic compression from the 59.90% trailing twelve-month gross margin, suggesting massive one-time cost of revenue charges. For the full trailing period, the operating margin is -29.92% and net margin is -32.45%, indicating the business is deeply unprofitable on a sustained basis. While there was a profitable Q2 2025 (net income of $196.89 million), the reversion to heavy losses in subsequent quarters underscores the lack of earnings consistency and raises red flags about the underlying business model's sustainability. The balance sheet shows a current ratio of 2.32, indicating adequate short-term liquidity, but the debt-to-equity ratio of 0.91 suggests a moderate level of leverage. More critically, the company burned significant cash, with trailing twelve-month free cash flow deeply negative at -$317.43 million. Return on equity is a poor -62.55%, and return on assets is nearly zero at 0.02%, reflecting extremely inefficient use of shareholder capital. The negative free cash flow, coupled with substantial quarterly net losses, indicates the company is dependent on external financing to fund operations and growth, increasing financial risk, especially in a challenging capital market environment for biotech.
Quarterly Revenue
$442934000.0B
2025-12
Revenue YoY Growth
-0.32%
YoY Comparison
Gross Margin
+0.09%
Latest Quarter
Free Cash Flow
$-317427000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SRPT Overvalued?
Given the company's negative trailing net income and negative EBITDA, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 1.03, while the forward-looking valuation can be inferred from the market cap of $2.26 billion against analyst consensus revenue estimates of $1.31 billion for the next period, implying a forward PS of approximately 1.72. The gap between the trailing and implied forward multiples suggests the market is pricing in a significant revenue recovery, but the elevated forward multiple relative to the trailing figure also reflects the current depressed sales base. Compared to typical biotechnology industry averages, which often trade at higher PS multiples due to growth expectations, Sarepta's PS ratio of ~1.0-1.7 appears at a discount, but this is justified by its recent severe revenue decline, lack of profitability, and high cash burn. The discount reflects deep skepticism about near-term execution and the sustainability of its commercial platform. The EV/Sales ratio of 1.0 further confirms the market is assigning a low multiple to current sales, pricing in substantial risk. Historically, Sarepta's valuation has been extremely volatile. The current PS ratio of 1.03 is near the bottom of its observable historical range, having fallen dramatically from levels above 40x seen in 2021 and 2022, and from 5.09x as recently as Q4 2025. Trading near historical lows suggests the market has priced in significant pessimism, potentially offering a value opportunity if the company can demonstrate a fundamental turnaround. However, it could also indicate the market anticipates further deterioration, such as sustained revenue declines or escalating losses.
PE
-3.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -106x~574x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-3.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and center on profitability and cash burn. The company's net margin is -32.45%, and it burned -$317.43 million in free cash flow over the trailing twelve months. The debt-to-equity ratio of 0.91 indicates moderate leverage, but the primary risk is dependency on external financing to fund operations given persistent losses. The extreme volatility in quarterly revenue—from $744.86M in Q1 2025 to $442.93M in Q4—and the gross margin collapse from 75.04% to 9.98% highlight operational instability and potential issues with product pricing, rebates, or inventory management that could persist.
Market & Competitive Risks are elevated due to the stock's valuation compression and binary outlook. While the trailing PS ratio of 1.03 appears discounted, it reflects deep market skepticism about the company's commercial execution. The stock's remarkably low beta of 0.255 indicates its price action is decoupled from the broader market, meaning investors are exposed almost entirely to company-specific, binary events like clinical data, regulatory decisions, or quarterly earnings surprises. Competitive risks in the DMD treatment landscape are constant, and any failure to successfully commercialize ELEVIDYS or defend market share for its exon-skipping therapies could lead to further multiple contraction.
Worst-Case Scenario involves a continuation of the current operational deterioration. A chain of events where Q4's gross margin collapse proves not to be a one-time charge but indicative of structural pricing pressure, coupled with revenue failing to rebound towards analyst estimates, would lead to accelerating cash burn and potential liquidity concerns. This could trigger a breach of the key $10.42 support level (the 52-week low), leading to panic selling. From the current price of $16.80, a realistic downside in this adverse scenario is a decline of approximately -38% to retest the $10.42 low, with potential for further losses if the business fundamentals erode beyond that point.
FAQ
The key risks are, in order of severity: 1) Financial Sustainability Risk: The company is deeply unprofitable (net margin -32.45%) and burning cash (-$317M TTM), creating dependency on external financing. 2) Operational Execution Risk: Extreme revenue volatility and the Q4 gross margin collapse to 9.98% indicate potential fundamental issues with pricing, rebates, or cost management that may not be temporary. 3) Commercialization Risk: The future value hinges on the successful adoption and potential label expansion of its gene therapy ELEVIDYS; any setbacks would crush the bull case. 4) Market Sentiment Risk: The stock's low beta of 0.255 means it moves on idiosyncratic news, leading to high volatility and potential for rapid, severe declines on negative updates.
The 12-month forecast is bifurcated with high uncertainty. Our analysis outlines three scenarios: a Bull Case (25% probability) with a target of $30-40, driven by successful ELEVIDYS adoption and margin recovery; a Base Case (50% probability) with a range of $18-25, assuming volatile but stabilizing fundamentals; and a Bear Case (25% probability) with a target of $10-15, triggered by continued operational deterioration. The base case is most likely, implying the stock may trade sideways to slightly higher as investors await consistent proof of a turnaround. The key assumption behind the base case is that gross margins recover partially but remain below historical peaks.
SRPT is undervalued relative to its own historical trading range but may be fairly valued given its current broken fundamentals. The trailing Price-to-Sales (PS) ratio of 1.03 is near historical lows, down from over 40x in 2021 and 5.09x in late 2025. This deep discount reflects the market's severe pessimism following the catastrophic Q4 2025 results. Compared to the broader biotech sector, which often trades at higher sales multiples for growth, SRPT's multiple is low, but this is justified by its lack of profitability and high cash burn. The valuation implies the market expects either a prolonged period of subpar performance or requires definitive proof of a turnaround before awarding a higher multiple.
SRPT is a high-risk, speculative buy only for investors with a strong stomach for volatility and a long time horizon. At a current PS ratio of 1.03, it is priced for disaster, offering significant upside if the company stabilizes. However, the recent 32.7% revenue decline and gross margin collapse to 9.98% present severe fundamental risks. The average analyst revenue estimate of $1.31B suggests a recovery is expected, but the wide estimate range highlights high uncertainty. It could be a good buy for deep-value, contrarian investors betting on a biotech turnaround, but it is not a good buy for most mainstream or risk-averse investors.
SRPT is unsuitable for short-term trading due to its low beta and company-specific, binary catalyst-driven price action, which makes timing entries and exits exceptionally difficult. It is only suitable for long-term investors (minimum 3-5 year horizon) who are betting on the multi-year commercial success of its DMD franchise and pipeline. The company is in a capital-intensive growth stage with no dividends, and earnings visibility is poor. Given the deep fundamental challenges, a long-term holder must be prepared for significant volatility and have the conviction that management can execute a multi-quarter turnaround. For most, it is a speculative holding within a diversified portfolio.